

Title (en)

COMPOSITIONS AND METHODS FOR TREATING ELEVATED BLOOD CHOLESTEROL

Title (de)

ZUSAMMENSETZUNGEN UND VERFAHREN ZUR BEHANDLUNG VON ERHÖHTEM BLUTCHOLESTEROLSPIEGEL

Title (fr)

COMPOSITIONS ET METHODES DE TRAITEMENT D'UNE CHOLESTEROLEMIE ELEVEE

Publication

**EP 1089731 A4 20030618 (EN)**

Application

**EP 99930451 A 19990621**

Priority

- GB 9817167 A 19980806
- US 9913887 W 19990621
- US 9052798 P 19980624

Abstract (en)

[origin: WO9966929A1] The present invention relates to compositions and methods for treating elevated blood cholesterol in a mammal while counteracting the occurrence of potentially adverse side effects such as myopathy. The compositions useful herein comprise the combination of a pharmaceutically effective amount of a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor ("HMG-CoA reductase inhibitor") and a geranylgeraniol compound to a mammal in need thereof.

IPC 1-7

**A61K 31/405**; **A61K 31/35**; **A61K 31/21**; **A61K 31/12**

IPC 8 full level

**A61K 31/045** (2006.01); **A61K 31/08** (2006.01); **A61K 31/215** (2006.01); **A61K 31/216** (2006.01); **A61K 31/22** (2006.01); **A61K 31/221** (2006.01); **A61K 31/351** (2006.01); **A61K 31/366** (2006.01); **A61K 31/40** (2006.01); **A61K 31/404** (2006.01); **A61K 31/405** (2006.01); **A61K 31/4164** (2006.01); **A61K 31/44** (2006.01); **A61K 31/443** (2006.01); **A61K 31/661** (2006.01); **A61P 3/06** (2006.01); **A61P 9/00** (2006.01); **A61P 9/10** (2006.01)

CPC (source: EP)

**A61K 31/221** (2013.01); **A61K 31/351** (2013.01); **A61K 31/40** (2013.01); **A61K 31/404** (2013.01); **A61K 31/44** (2013.01); **A61P 3/06** (2017.12); **A61P 9/00** (2017.12); **A61P 9/10** (2017.12)

Citation (search report)

- [Y] US 5691375 A 19971125 - BEHOUNEK BRUCE D [US], et al
- [Y] EP 0671170 A1 19950913 - BRISTOL MYERS SQUIBB CO [US]
- [Y] US 5622985 A 19970422 - OLUKOTUN ADEOVE Y [US], et al
- [Y] GB 2055100 A 19810225 - SANKYO CO
- [A] WO 9719091 A1 19970529 - BALDACCI LAB SPA [IT], et al
- [Y] FLINT OLIVER P ET AL: "Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induced myotoxicity in vitro.", TOXICOLOGY AND APPLIED PHARMACOLOGY, vol. 145, no. 1, 1997, pages 91 - 98, XP002237082, ISSN: 0041-008X
- [A] PATENT ABSTRACTS OF JAPAN vol. 199, no. 809 31 July 1998 (1998-07-31)
- See references of WO 9966929A1

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE

DOCDB simple family (publication)

**WO 9966929 A1 19991229**; AU 4698999 A 20000110; AU 754767 B2 20021121; CA 2335366 A1 19991229; EP 1089731 A1 20010411; EP 1089731 A4 20030618; JP 2002518448 A 20020625

DOCDB simple family (application)

**US 9913887 W 19990621**; AU 4698999 A 19990621; CA 2335366 A 19990621; EP 99930451 A 19990621; JP 2000555615 A 19990621